Bridging the Gap in Retinal Care
BioPhotonix is ending the era of passive observation.
We are engineering the shift from monitoring disease to active, accessible intervention—bridging the gap between diagnosis and care for the world’s 2nd leading cause of blindness.
BioPhotonix was founded on a single, uncompromising belief:
Early intervention is the only way to preserve independence.
We are building the world’s first scalable, system-optimised photobiomodulation platform—converting 'nothing can be done' into a structured, evidence-led clinical pathway.
Our Origin
The current care pathway for dry AMD is structurally broken.
​
As diagnostic technology in community optometry has advanced, we are identifying retinal disease earlier than ever before. Yet, for millions of patients, this early diagnosis is followed by a "watch and wait" approach. Patients are monitored as their vision inevitably declines, simply because effective hospital-grade interventions are not scalable to the community setting.
​
We were established to close this gap. By translating the science of Photobiomodulation (PBM) into a regulated, portable medical platform, we are empowering optometrists to intervene early—preserving vision and independence for the aging population.
​
With the global economic burden of AMD exceeding $49 billion annually and millions losing their independence, BioPhotonix is not just building a device. We are building the infrastructure for the future of global eye health.
Safety-Accessibility
We are not a wellness company. BioPhotonix is built on the principles of regulated medical technology.
Clinician-Led
We believe powerful therapy requires expert supervision.
Our technology is designed to be initiated and monitored by eye-care professionals.
Evidence-First
We prioritise clinical validation and regulatory compliance over speed-to-market.
Patient-Centric
We measure success not just by clinical biomarkers, but by the preservation of patient independence.
Leadership
Founder & Director
Adail Islam
BSc Optom
BSc Orthoptics
Founder & Director
Adail is an Optometrist and Orthoptist with extensive clinical experience managing macular disease across both hospital ophthalmology pathways and community optometry settings.
​
His direct experience on the front lines of eye care revealed the limitations of existing treatments—specifically, that hospital-bound technologies could not scale to meet the needs of the millions of patients managed in primary care. Adail founded BioPhotonix to engineer a solution that fits the reality of clinical practice: a device that is clinically rigorous, regulator-ready, and accessible enough to be deployed in every community clinic.
Strategic Advisors & Development Partners
Dr Nikola Krstajic
PhD & Lecturer - Medical Physics
Scientific & Clinical Advisory
Working in collaboration with academic experts, including Dr Nikola Krstajic (University of Dundee), to ensure our device parameters are grounded in the latest photobiological research and retinal safety standards.​​
Edwin Lindsay
Managing Director at Compliance Solutions
Strategic guidance provided by Compliance Solutions Life Sciences, ensuring our Quality Management System (ISO 13485) and regulatory pathways (UKCA/CE) meet the highest standards of medical device governance.
Martin Pacitti
Project Manager at WideBlue
Our development roadmap is executed in partnership with leading medical design houses, ensuring Revolux is built to rigorous industrial and ergonomic standards.